TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.
Frequently asked questions
What sector does Taigen Biopharmaceuticals Holdings Ltd (4157) operate in?
Taigen Biopharmaceuticals Holdings Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Taigen Biopharmaceuticals Holdings Ltd (4157) current stock price?
As of the latest data, Taigen Biopharmaceuticals Holdings Ltd stock price is NT$9.13, with a previous close of NT$9.13.
What is Taigen Biopharmaceuticals Holdings Ltd (4157) current market capitalization?
Taigen Biopharmaceuticals Holdings Ltd market cap is approximately 6.50 billion.
What is Taigen Biopharmaceuticals Holdings Ltd (4157) Earnings Per Share (EPS)?
The trailing EPS is NT$0.07.
What is Taigen Biopharmaceuticals Holdings Ltd (4157) Price-to-Earnings (P/E) ratio?
Taigen Biopharmaceuticals Holdings Ltd current P/E ratio is 130.43.
Does Taigen Biopharmaceuticals Holdings Ltd (4157) pay dividends?
No. Taigen Biopharmaceuticals Holdings Ltd does not pay a dividend.
What is Taigen Biopharmaceuticals Holdings Ltd (4157) beta (volatility) score?
Taigen Biopharmaceuticals Holdings Ltd has a beta of 0.206, indicating lower volatility than the overall market.
